{"entity":{"id":"nci-csrn","kind":"institution","name":"NCI Cancer Screening Research Network (CSRN)","aka":["CSRN","Cancer Screening Research Network"],"tldr":"A US National Cancer Institute network, led by Fred Hutch Cancer Center in Seattle, that tests new ways of screening for cancer. Its first study, Vanguard, is checking whether blood tests that look for many cancers at once can be studied properly in a large trial.","summary":"The NCI Division of Cancer Prevention describes the CSRN as a multi-centre effort, led by Fred Hutch Cancer Center, to examine the effectiveness of emerging technologies for cancer screening, with ACCESS hubs that enrol participants and coordinating centres. Its first study is the Vanguard Study, which will enrol up to 24,000 people, randomised to a control arm or to one of two multi-cancer detection test arms, to inform the design of a much larger randomised trial of whether the benefits of such tests outweigh the harms and whether they reduce deaths. The two assays selected, in NCI's alphabetical order, are the Avantect MCD Test (ClearNote Health) and the Shield MCD Test (Guardant Health), provided without cost to participants and not compared with each other. The NCI Moonshot page lists the creation of the CSRN and support for Vanguard among the Moonshot's accomplishments.","asOf":"2026-11-04","links":[{"label":"Cancer Screening Research Network (NCI Division of Cancer Prevention)","url":"https://prevention.cancer.gov/major-programs/cancer-screening-research-network-csrn"},{"label":"The Vanguard Study (NCI)","url":"https://prevention.cancer.gov/major-programs/cancer-screening-research-network-csrn/vanguard-study"}],"tags":["research-funding"],"related":[],"cancers":[],"sections":[],"technologies":["mced"],"targets":[],"drugs":["avantect-mcd","shield-mcd"],"companies":["clearnote-health","guardant-health"],"institutions":["nci","fred-hutch"],"pathways":[],"terms":[],"trials":["vanguard-study"],"people":[],"bottlenecks":["b-early-detection","b-overdiagnosis"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Placed at Fred Hutch in Seattle, the lead institution named by NCI. The number of ACCESS hubs and their names were not read and are left out.","The Vanguard Study already has a trial record (vanguard-study, NCT06995898); this record is the network that runs it."],"city":"Seattle","country":"US","lat":47.627,"lng":-122.332,"institutionType":"consortium","website":"https://prevention.cancer.gov/major-programs/cancer-screening-research-network-csrn","programs":["Vanguard Study of multi-cancer detection tests","CSRN ACCESS hubs","CSRN coordinating centres"]},"route":"/institutions/nci-csrn/","neighbours":{"technology":[{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"avantect-mcd","kind":"drug","name":"Avantect Multi-Cancer Detection Test","route":"/drugs/avantect-mcd/"},{"id":"shield-mcd","kind":"drug","name":"Shield MCD (Shield Multi-Cancer Detection)","route":"/drugs/shield-mcd/"}],"company":[{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/"},{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"trial":[{"id":"vanguard-study","kind":"trial","name":"Vanguard Study (NCI Cancer Screening Research Network)","route":"/trials/vanguard-study/"}],"bottleneck":[{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}]}}